Last reviewed · How we verify
surufatinib + gemcitabine + nab-paclitaxel
surufatinib + gemcitabine + nab-paclitaxel is a Tyrosine kinase inhibitor Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital. It is currently in Phase 3 development for Advanced pancreatic neuroendocrine tumors, Advanced malignant pancreatic cancer.
Surufatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR).
Surufatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR). Used for Advanced pancreatic neuroendocrine tumors, Advanced malignant pancreatic cancer.
At a glance
| Generic name | surufatinib + gemcitabine + nab-paclitaxel |
|---|---|
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Drug class | Tyrosine kinase inhibitor |
| Target | VEGFR, PDGFR, FGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death in rapidly dividing cancer cells. Nab-paclitaxel is a formulation of paclitaxel that targets cancer cells by disrupting microtubule function, leading to cell cycle arrest and apoptosis.
Approved indications
- Advanced pancreatic neuroendocrine tumors
- Advanced malignant pancreatic cancer
Common side effects
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Anemia
- Neutropenia
- Thrombocytopenia
- Anorexia
- Weight loss
- Hypersensitivity reactions
Key clinical trials
- Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer (PHASE3)
- Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (PHASE2)
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PHASE2, PHASE3)
- Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer (PHASE2)
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer (PHASE2)
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (PHASE1, PHASE2)
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer (PHASE1, PHASE2)
- The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- surufatinib + gemcitabine + nab-paclitaxel CI brief — competitive landscape report
- surufatinib + gemcitabine + nab-paclitaxel updates RSS · CI watch RSS
- Tianjin Medical University Cancer Institute and Hospital portfolio CI
Frequently asked questions about surufatinib + gemcitabine + nab-paclitaxel
What is surufatinib + gemcitabine + nab-paclitaxel?
How does surufatinib + gemcitabine + nab-paclitaxel work?
What is surufatinib + gemcitabine + nab-paclitaxel used for?
Who makes surufatinib + gemcitabine + nab-paclitaxel?
What drug class is surufatinib + gemcitabine + nab-paclitaxel in?
What development phase is surufatinib + gemcitabine + nab-paclitaxel in?
What are the side effects of surufatinib + gemcitabine + nab-paclitaxel?
What does surufatinib + gemcitabine + nab-paclitaxel target?
Related
- Drug class: All Tyrosine kinase inhibitor drugs
- Target: All drugs targeting VEGFR, PDGFR, FGFR
- Manufacturer: Tianjin Medical University Cancer Institute and Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced pancreatic neuroendocrine tumors
- Indication: Drugs for Advanced malignant pancreatic cancer
- Compare: surufatinib + gemcitabine + nab-paclitaxel vs similar drugs
- Pricing: surufatinib + gemcitabine + nab-paclitaxel cost, discount & access